Tag: Policy

  • FTC Sends Warning Letters to 24 Healthcare Organizations Over Price Transparency

    FTC Sends Warning Letters to 24 Healthcare Organizations Over Price Transparency

    The Federal Trade Commission sent warning letters to 24 of the “nation’s largest” healthcare services companies, citing concerns that they may be failing to provide transparent price information.

    The letters were signed by FTC Chairman Andrew N. Ferguson. The agency did not disclose which organizations it sent the letters to.

    It notes in the letter that Section 5 of the FTC Act requires these organizations to provide patients with “timely, accurate, and complete pricing for healthcare services, especially for non-emergency services that are scheduled in advance.” The agency urged the organizations to conduct a review of their pricing practices and make changes if they find they’re in violation of the FTC Act. 

    The letter also stated that price transparency is a major priority of the FTC across several sectors, including rental housing, hotels and grocery delivery services. Consumers can’t compare offerings and make informed decisions without price transparency, the letter said.

    “Price transparency is particularly critical in the hospital and healthcare setting because healthcare is often one of the most significant and financially burdensome costs consumers face,” Ferguson wrote in the letter. “Patients frequently must invest substantial time and effort to travel for in‑person visits, making it even more important that they understand costs upfront before committing to care. Moreover, hospitals and healthcare facilities can charge dramatically different prices for the same services, leaving consumers vulnerable to wide and often unexpected cost discrepancies.”

    CMS requires hospitals to publicly disclose pricing information for healthcare services through machine-readable files and consumer-friendly pricing information. They also must provide uninsured and self-pay patients with good-faith estimates of expected charges before scheduled care. However, the FTC stated that complying with CMS price transparency requirements doesn’t necessarily mean a healthcare provider is complying with the FTC Act, which may impose additional requirements. 

    The letter notes that the price of healthcare services is a “material term,” meaning “clear and conspicuous disclosures” are needed so consumers are not deceived.

    “Accordingly, failing to disclose the price of a healthcare service may be deceptive if it is likely to mislead consumers acting reasonably under the circumstances,” Ferguson wrote. “Even when some price terms are disclosed, disclosures may be deceptive when they are incomplete — such as when they omit certain charges like physician fees or facility fees, or cover only a portion of the expected care — because consumers may reasonably believe they have been provided the total cost of care. Likewise, inaccurate disclosures mislead consumers and cause substantial harm.”

    The FTC said the letters do not conclude that the recipients violated the FTC Act. 

    Photo: Oleksandr Hruts, Getty Images

  • STAT+: Are stem cell treatments about to have their day?

    STAT+: Are stem cell treatments about to have their day?

    You’re reading STAT’s D.C. Diagnosis newsletter

    Adobe

    John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.

    You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

    Celebrity doctor Mike Varshavski has been contacted by The Bachelor for its 30th season. Send news tips and hot physicians to [email protected] or John_Wilkerson.07 on Signal.

    A lame lame-duck

    On Friday, President Trump said he will give $90 to more than 20 million seniors to help pay for Medicare premiums.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.

  • Trump Administration Announces $90 Payments to Help Cover Medicare Part B Premiums

    Trump Administration Announces $90 Payments to Help Cover Medicare Part B Premiums

    Little pink ceramic piggy bank pattern on the left side on yellow background. Concept of saving money, savings.

    On Friday, President Donald Trump announced that the federal government is making one-time payments of $90 per person for more than 20 million people to help them pay for Medicare Part B premiums.

    These payments are coming from the Medicare Improvement Fund, which is meant to make improvements to the Medicare fee-for-service program and has been given $2 billion by Congress. Eligible seniors will receive the payment via a direct deposit in early October. 

    According to a fact sheet, those whose premiums are paid by Medicaid or who pay an Income-Related Monthly Adjustment Amount don’t qualify for payments. Those enrolled in private Medicare Advantage plans also aren’t eligible.

    This one-time payment likely won’t do much when it comes to offsetting rising healthcare costs, noted Juliette Cubanski, vice president and director of the Program on Medicare Policy at KFF, in a recent post.

    Currently, Medicare’s standard Part B premium is $2,435 and is expected to increase by $79 annually for 2027, according to KFF. This means that “this increase alone would consume most of the $90 payment,” Cubanski noted. In addition, beneficiaries will likely see healthcare costs rise in other ways, such as deductibles and cost sharing for medical and drug benefits.

    Cubanski also compared these $90 payments to a similar proposal announced by Trump ahead of the 2020 election, which involved a $200 drug card to offset out-of-pocket drug costs for Medicare beneficiaries.

    “The cards were to be provided under a Section 402 demonstration designed to test whether lowering out-of-pocket drug costs would improve medication adherence, reduce unnecessary health care use, and lower Medicare spending,” Cubanski said. “Ultimately, the drug cards were never sent, amid questions about the design of the experiment and its nearly $8 billion projected cost.”

    Cubanski noted that the $90 payments will mostly deplete the Medicare Improvement Fund.

    These payments also come after the Trump administration announced in September $500 refunds per person to nearly 1 million Americans with Affordable Care Act coverage. One healthcare expert previously told MedCity News that these checks will do little to address healthcare affordability.

    “There is no question that $500 matters to a family struggling to pay its bills, and Americans are struggling,” said Dr. Adam Brown, an emergency physician and founder of ABIG Health. “Healthcare costs are a significant part of that burden. But we have to put this refund into context. For someone paying the full cost of an ACA plan, $500 doesn’t even cover one month’s average premium. … Ultimately, we shouldn’t confuse a check with a healthcare affordability strategy.”

    Photo: DBenitostock, Getty Images

  • STAT+: New Trump regulations would clean up health care pricing disclosures

    STAT+: New Trump regulations would clean up health care pricing disclosures

    Public drug price information is now coming next year, Trump officials say

    Mehmet Oz at a federal event on Monday in Washington announcing new health care price transparency rules.Finn Gomez/Getty Images

    By Bob Herman

    Oct. 5, 2026

    Bob Herman is the author of Health Care Inc., an award-winning weekly newsletter about the business of health and medicine.

    Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.

    The Trump administration released new regulations Monday that will force health insurance companies to publish cleaned-up spreadsheets of the prices that they pay hospitals and doctors, while stripping out meaningless data that clogged up the files.

    Trump officials also said they will start developing the system for disclosing prescription drug prices next month. A “hopeful” final plan for drug pricing data will come out by next May, said Mehmet Oz, the head of Medicare and Medicaid, at an event Monday. The government will enforce those requirements by the end of 2027. 

    Last year, the Trump administration punted on finalizing drug price disclosure rules, in a victory for drug companies and pharmacy benefit managers that have fiercely guarded their prices. 

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. Business of Health Care Reporter

      Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.

  • STAT+: Utah plows ahead with more health AI pilots for prescriptions, women’s health

    STAT+: Utah plows ahead with more health AI pilots for prescriptions, women’s health

    Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

    Utah regulators on Monday announced a plan to allow an artificial intelligence product to evaluate patients for acne treatment and write new drug prescriptions without prior human review. 

    A startup called Nolla Health will launch an AI-powered service in the state that will assess a patient for mild-to-moderate acne treatment using a structured intake and by analyzing photos of their skin. The product may determine whether one of a list of low-risk drugs is appropriate. In the first stages of the pilot, the decisions of the AI will be reviewed by a licensed clinician who will sign off on prescriptions, but Nolla may eventually be allowed to prescribe drugs without this review. The company last year announced it raised $4.5 million from investors including General Catalyst, and Nolla aspires to direct treatment for a host of conditions using AI.

    The new pilot is part of a significant expansion of a closely watched “AI sandbox” program that allows Utah’s Office of Artificial Intelligence Policy, or OAIP, to waive regulations, including around the practice of medicine, for companies that want to test AI products under state supervision. 

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • Trump’s ACA Fraud Crackdown: Experts Urge Going After Bad Actors, Not Patients

    Trump’s ACA Fraud Crackdown: Experts Urge Going After Bad Actors, Not Patients

    Addressing fraud, waste and abuse in healthcare has been a major focus of the Trump Administration, particularly with the creation of the White House Task Force to Eliminate Fraud. Last week, the task force took a rather aggressive tactic, announcing that it will cancel 315,000 unauthorized enrollments covering more than 760,000 individuals in the Marketplace. The move, however, is being criticized by many in the medical industry.

    The administration anticipates that this will return about $2.2 billion in taxpayer-funded subsidies.

    “We are shutting down unauthorized Marketplace enrollments and returning approximately $2.2 billion in taxpayer-funded subsidies,” said HHS Secretary Robert F. Kennedy, Jr., in a statement. “CMS is strengthening safeguards, pursuing bad actors, and holding agents and brokers accountable when they break the rules. Under President Trump, HHS will protect Americans’ health coverage and ensure taxpayer dollars reach the people they are intended to serve.”

    One healthcare expert argued that while there’s a need to address fraud in the Marketplace, patients shouldn’t be the ones punished.

    “I agree we have to be going after bad actors, but we can’t be going after the patients,” said Dr. Adam Brown, an emergency physician and founder of ABIG Health.

    Brown emphasized that these efforts can’t be looked at in isolation. The enhanced ACA premium tax credits expired at the end of 2025, increasing premiums for many Marketplace enrollees. In addition, the Trump administration is implementing Medicaid work requirements that states generally must begin by 2027.

    “If you look at these things in isolation, you have a tendency to anchor to, ‘Well, that’s not a lot of people,’ or ‘I’m sure a lot of those individuals that are within that 760,000 number are not real individuals,’” Brown said. “But that all said, when you kind of look at all of these pieces of the puzzle, it makes me question: Are we trying to dismantle some of the important social service safety net type of programs in the country that so many people depend on, without a very clear alternative right now that’s affordable that gives them the necessary access?”

    Brown urged CMS to establish a formal process for reinstating people who were wrongly disenrolled. He also called on Congress to extend the ACA tax credits.

    Families USA, a patient advocacy organization, also spoke out against the decision.

    “Once again, the Trump administration is using alleged fraud accusations as a political smokescreen to double down on what they are actually doing: taking health coverage away from hundreds of thousands of people,” said Anthony Wright, executive director of Families USA. “Real fraud should be stopped, especially dishonest brokers who sign people up without their knowledge. Previously, anti-fraud policies and procedures banned those brokers, but this administration reinstated them. Now families, not bad actors, are paying the price.” 

    This comes as recent research from the National Bureau of Economic Research found that the broader implementation of the ACA was associated with an estimated 20% to 30% reduction in mortality among people who were uninsured before the law.

    With the administration’s decision to remove 760,000 people from ACA coverage, it’s important to note that not all of those people will become uninsured, noted one of the paper’s authors, Robert Kaestner, research associate at the University of Chicago. 

    “The majority of them are going to have access to other types of health insurance… So 250,000 people who might end up uninsured out of a country of 333 million — that’s not a big change, but still, it’s 250,000 people potentially without health insurance. That’s a very serious consequence,” Kaestner estimated.

    Photo: illustration, Getty Images

  • STAT+: What health tech leaders are talking about in Washington policy circles

    STAT+: What health tech leaders are talking about in Washington policy circles

    You’re reading the web edition of STAT’s AI Prognosis newsletter

    STAT/Adobe

    Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01.

    This is the web edition of STAT’s AI Prognosis newsletter, our guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. 

    It never crossed my mind that there would be a Cookie Monster AI satire piece in the New Yorker, but it does exist and I love it so much. h/t to my colleague Sarah Todd for sharing “Cookie Monster Tries to Meet His A.I. Mandate.”

    News I missed, story tips, comments: [email protected]

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01.

  • STAT+: The last ‘breakthrough’ devices to get special treatment from Medicare

    STAT+: The last ‘breakthrough’ devices to get special treatment from Medicare

    Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer telehealth. Confidential tips can be sent on Signal at palmer.01.

    In the last month, manufacturers have announced “breakthrough” status from the Food and Drug Administration for a menagerie of devices: triage algorithms for abdominal CT scans, diagnostic panels for urinary tract infections, and thrombectomy robots, to name a few.

    They’re coming in just under the wire: As of October, new breakthrough-designated devices will no longer be eligible for special treatment when it comes to qualifying for extra Medicare payments. These devices, and more than a dozen others, are included in the latest update of STAT’s Breakthrough Device Tracker, which since 2022 has captured nearly 800 devices reported to have FDA breakthrough status. 

    In August, the Centers for Medicare and Medicaid Services finalized the removal of pathways that have made it easier for breakthrough devices to qualify for supplementary Medicare payments for both inpatient and outpatient use. Since 2020, devices that received the designation from the FDA have been able to qualify for new technology add-on payments and transitional pass-through payments without proving they provide a substantial clinical improvement over alternatives, or that they are new. 

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoring

    STAT+: UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoring

    Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

    Major insurers are pushing back on a Medicare proposal that would significantly disrupt how many doctors bill for tracking the health of patients using devices like connected blood pressure cuffs, scales, and blood glucose meters. These remote monitoring services help patients manage a range of medical conditions, including hypertension, diabetes, and heart failure.

    UnitedHealth Group, CVS Health, and Kaiser Permanente all wrote letters to the Centers for Medicare and Medicaid Services opposing a proposal that would require that remote patient monitoring care be delivered by direct employees of the practice that is billing for them — effectively banning providers from using contractors for the care. All of these groups operate both insurers and care organizations.

    The opposition from UnitedHealth Group is notable in particular because the company’s insurance subsidiary, UnitedHealthcare, recently attempted to stop paying for most remote patient monitoring “due to insufficient evidence of efficacy.”

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe